Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: The efficacy and safety of fingolimod for relapsing-remitting multiple sclerosis (RRMS) had been well verified in several large randomized controlled trials (RCTs) during the past decade. However, there are fewer systematic comparisons of different doses of fingolimod and whether the dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xin, Xue, Tao, Wang, Zilan, Chen, Zhouqing, Zhang, Xuwei, Zhang, Wei, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165387/
https://www.ncbi.nlm.nih.gov/pubmed/34079453
http://dx.doi.org/10.3389/fphar.2021.621856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165387/
https://www.ncbi.nlm.nih.gov/pubmed/34079453
http://dx.doi.org/10.3389/fphar.2021.621856

Ejemplares similares